# Quest Diagnostics Incorporated (DGX) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $237.14, market value $26.2 billion.

## Valuation
- **P/E (trailing): 25.2×** (5-yr avg 16.9×, 3-yr avg 18.7×). Quest Diagnostics Incorporated trades at 25.2× trailing earnings, well above its own five-year average of 16.9×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 19.7×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.43**. A PEG of 1.43 is in the range usually read as fairly priced for its growth.
- **Price / sales: 2.3×**. Each dollar of revenue is priced at 2.3×.
- **Price / book: 3.5×**. The shares trade at 3.5× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 14.2×**. Enterprise value is 14.2× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 5.2%** (5-yr avg 7.0%). Free cash flow equals 5.2% of the market value, below its five-year average of 7.0%, so the shares are pricier on cash than usual. Above 5% is generally attractive.
- **Earnings yield: 4.0%**. The inverse of the P/E: 4.0% of the price is earned each year.

## Profitability
- **Operating margin: 14.1%**. 14.1% of revenue is left after running the business.
- **Net margin: 9.0%**. 9.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 13.8%**. 13.8% on shareholders' equity is solid.
- **Return on invested capital: 10.4%**. Return on all capital, debt included, is 10.4%.
- **Return on assets: 6.5%**. Each dollar of assets produces 6.5% of profit.

## Growth
- **Revenue growth (1 yr): 11.8%** (3-yr 3.7%/yr, 5-yr 3.2%/yr). Revenue grew 11.8% over the last year, against 3.2% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 13.8%** (3-yr 3.2%/yr, 5-yr -3.5%/yr). Earnings per share rose 13.8%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 1.1%/yr**. Free cash flow has compounded at 1.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.79**. Debt is 0.79 times equity, moderate leverage.
- **Net debt / EBITDA: 2.4×**. It would take 2.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 1.45%** ($3.32 per share, trailing). Quest Diagnostics Incorporated yields 1.45%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 36%** (27% of free cash flow). 36% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 22**. 22 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 7.3%/yr** (1-yr 6.4%). The dividend has grown 7.3% a year over five years.

## Price and momentum
- **Total return (1 yr): 34.0%** (YTD 38.4%, 3-mo 18.9%). The shares are up 34.0% over twelve months including dividends.
- **From 52-week high: -4.1%** (38.5% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): -0.15** (volatility 24%). Beta of -0.15 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DGX · Page: https://foliofundamentals.com/stocks/dgx

Not investment advice.